Recent CDC data revealed an estimated 25,000 emergency room visits related to semaglutide weight loss drugs between 2022 and 2023, with the majority involving severe gastrointestinal complications requiring hospitalization
Who Should Not Be Introduced to GLP-1 Immediately
These findings are not surprising, Mir Ali, MD, a bariatric surgeon, bariatric medicine specialist and medical director of MemorialCare Surgical Weight Loss Center at Orange Coast Medical Center in Fountain Valley, CA, told Medical News Today
Not just weight loss, but an improvement in the underlying metabolic dysfunctions driving these conditions
GLP-1 receptor agonist-associated tumor adverse events: a real-world study from 2004 to 2021 based on FAERS
Discussion The GLIDE trial aimed to assess the metabolic impact of the addition of a GLP-1 receptor agonist in the form of liraglutide 1.8 mg once daily following a LAGB in patients with T2DM